Hays Waldrop Discusses How The Institute of Healthcare Executives and Suppliers Provides Value Through the Exchange of Industry Knowledge and Experience”

Technology is in a constant state of change, especially with new innovations in healthcare happening every day. But it’s not always easy to know what’s out there, or to get your product to market. In today’s connected world, it has become more important than ever to have a community that you can chat with, learn from, and bounce ideas off of. Networking is in.

But how do networking events in healthcare bring value to the industry?

On the latest episode of I Don’t Care with Host Kevin Stevenson, guest Hays Waldrop, Founder and President of the Institute of Healthcare Executives and Suppliers, discusses the foundation of IHES and the importance of networking in the healthcare field.

Waldrop’s ‘Aha!’ moment came when he was working with a start-up in healthcare that had a product catered towards those with learning disabilities. While the doctors and healthcare professionals loved the product, so too, did schools. So when he saw the superintendents and leaders of school districts gathered to network and chat about different products, he had a realization: why wasn’t this happening in healthcare?

So, over the course of 20 years, Waldrop networked to form a conglomerate of healthcare professionals. “We’ve got a CEO group, I’ve got a supply-chain group, and also a pharmacy group, and so we come together and it’s a live-event business and we connect providers and suppliers in this environment.”

The two also discussed…

  • The different events IHES holds and how it creates a positive learning environment
  • What type of sessions and networking events there are and who attends
  • What the criteria are for adding in newer suppliers and start-ups

“You know, if you’re just the same old ‘me too’ commodity, that’s not real attractive necessarily, they’re necessary and yeah we clearly have those…but it’s always cool when you have a new technology, something different that the executives perhaps have not seen before or maybe they’re doing it just differently…,” said Waldrop.

Hays Waldrop has over 25 years of experience in the healthcare industry, having first started working in Territory Sales for Biomet, an orthopedic implant company. After working with a few start-ups around the dot com boom, Waldrop formed IHES, a group of three networking and learning platforms for healthcare executives and suppliers. He is a graduate of the University of Tennessee, Knoxville.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More